



Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization
05 Oct – 07 Oct 2020
Virtual Meeting
Agenda

Monday, 05 October 2020

Time	Session	Purpose of session, target outcomes and questions for SAGE	Duration
10:00	Closed SAGE meeting	Preparation of the sessions of the day. Other important discussion items.	1h
11:00	Break	Break	15 min
11:15	Opening and welcome – introduction of participants A. CRAVIOTO. Chair of SAGE. 10 min.	Opening of the Plenary Meeting	10 min.
11:25	Global Reports - Session 1 Report from the Director of IVB. K. O'BRIEN. WHO. 20 min. Update from Gavi. S. BERKLEY. GAVI. 10 min. Discussion. 15 min.	FOR INFORMATION	45 min.
12:10	Break	Break	15 min.
12:25	Immunization in the context of the COVID-19 pandemic, including regional and country focus – Session 2 A. Impact of the COVID-19 pandemic on immunization activities Introduction to session. N. MACDONALD. SAGE Member. 5 min. Impact of COVID-19 on immunization programme implementation: Regional situation reports and country highlights: <ul style="list-style-type: none"> • Presentations (8 min presentation per region). 50 min. • Discussion. 30 min. (in total) Update on global monitoring and activities to support resumption of services. D. CHANG BLANC. WHO. 10 min. Discussion. 10 min. Revised statement on guiding principles. Framing of the issues. N. MACDONALD. SAGE Member. 5 min. Discussion. 30 min.	FOR DISCUSSION AND DECISION To update SAGE on the programmatic impact of COVID-19 and request appraisal of a new version of ' <i>Guiding Principles for immunization activities during the COVID-19 pandemic</i> '.	2h 20 min.
14:45	Break	Break	15 min.

15:00	B. Briefs to review evidence for COVID-19 co-morbidity and benefit of vaccination in relation to Influenza and Pneumococcus	FOR INFORMATION	30 min.
	<ul style="list-style-type: none"> Influenza. M. FRIEDE. WHO. 10 min. Pneumococcal disease. S. DESAI. WHO. 10 min. <p>Discussion. 10 min.</p>		
15.30	Rotavirus vaccines - Session 6	FOR DECISION	1h
	<p>Introduction to session, background and key questions. K. NEUZIL. SAGE Member. 10 min.</p> <p>Systematic review of evidence on efficacy, effectiveness, and safety. N. HENSCHKE. Cochrane Response. 10 min.</p> <p>Overview of findings and proposals from the SAGE Ad-hoc Working Group. K. NEUZIL. SAGE Member. 10 min.</p> <p>Discussion. 30 min.</p>	<p>Present SAGE with updated evidence on efficacy, effectiveness and safety of rotavirus vaccines and on programmatic experience with using rotavirus vaccines.</p> <p>SAGE is requested to address the following questions:</p> <ul style="list-style-type: none"> Does the evidence on the safety and efficacy for Rotavac and Rotasiil support a WHO recommendation for global use? Can recommendations for the 4 currently prequalified rotavirus vaccines (Rotarix, RotaTeq, Rotavac, and Rotasiil) be generic? Can recommendations for upcoming similar vaccines be generic? If not, what recommendations need to be specified by product? In the context of the disruption due to the COVID-19 pandemic or other immunization system disruptions, are there special considerations for rotavirus vaccination catch-up? If yes, what are they? <p>What are the clinical and programmatic research questions needed to generate data for future policy and program decisions?</p>	
16:30	End of the day		

Tuesday, 06 October 2020

10:00	Closed SAGE meeting	Preparation of the sessions of the day. Recap of day 1. Other important discussion items.	1h
11:00	Break	Break	15 min.
11:15	Polio - Session 4	FOR DECISION	1h 30 min.
	<p>Update from the Global Polio Eradication Initiative. M. ZAFFRAN. WHO. 10 min.</p> <p>Observations to global update from SAGE Polio Working Group I. JANI. SAGE Member. 5 min.</p> <p>Questions: 5 min.</p> <p>Two-dose IPV routine immunization schedule</p> <ul style="list-style-type: none"> Immunogenicity data from trials with 2-dose IPV and fIPV. O. MACH. WHO. 5 min. Options for 2nd dose introduction D. CHANG-BLANC. WHO. 5 min. 	<p>SAGE will be informed on the current status of the polio eradication program in the context of COVID-19 and on nOPV2 development.</p> <p>SAGE is asked to review the evidence and make recommendations on:</p> <ul style="list-style-type: none"> Recommendation on 2nd IPV dose in routine immunization. GPEI 'type 2' vaccine use framework. Recommendation on use of IPV for poliovirus outbreak response. 	

<p>Proposals on two-dose IPV schedule from the SAGE Polio WG I. JANI. SAGE Member. 5 min.</p> <p>Questions: 5 min.</p> <p>Update on nOPV2 development</p> <ul style="list-style-type: none">Emergency Use Listing Procedure (EUL) process. C. RODRIGUEZ. WHO. 5 min.Proposed 'type 2' vaccine use framework. G. MACKLIN. WHO. 5 min. <p>Proposals on nOPV from the SAGE Polio Working Group. I. JANI. SAGE Member. 5 min.</p> <p>Questions: 5 min.</p> <p>Remaining items to report from the SAGE Polio Working Group including considerations for IPV use in poliovirus outbreak response. I. JANI. SAGE Member. WHO. 10 min.</p> <p>Discussion. 20 min.</p>			
12:45	Break	Break	30 min.
13:15	COVID-19 vaccination – Session 3 (part 1)	FOR DECISION	1h 30 min.
<p>Session objective setting and vaccine landscape overview. H. NOHYNEK. SAGE Member. 10 min.</p> <p>Update on COVAX. K. O'BRIEN. WHO. 5 min.</p> <p>GACVS update on COVID19 Vaccine Safety. D.S. AKRAM. GACVS Vice-Chair. 10 min.</p> <p>Discussion. 15 min.</p> <p>Burden of disease and at-risk populations. A. WILDER-SMITH. WHO. 10 min.</p> <p>Vaccine impact modelling: preliminary results. N. GRASSLY, Imperial College London and S. PALLAS, US CDC. 20 min.</p> <p>Discussion. 20 min.</p>		<p>What key aspects should be considered in the prioritization of target populations for Covid-19 vaccination under vaccine supply constraint?</p>	
14:45	Break	Break	15 min.
15:00	COVID-19 vaccination – Session 3 (part 2)	FOR DECISION	1h
<p>Prioritization and potential use case scenarios. S. OMER. Yale Institute for Global Health and R. FADEN. Johns Hopkins University. 20 min.</p> <p>Discussion. 40 min.</p>		<p>What key aspects should be considered in the prioritization of target populations for Covid-19 vaccination under vaccine supply constraint?</p>	
16:00	End of the day		

Wednesday, 07 October 2020

10:00	Closed SAGE meeting	Preparation of the sessions of the day. Recap of day 2. Other important discussion items.	1h
--------------	----------------------------	-------------------------------------------------------------------------------------------	----

11:00	Break	Break	15 min.
11:15	Measles Rubella Strategic Framework - Session 7 Introduction to session and key questions. K. MULHOLLAND. SAGE Member. 5 min. Presentation of the Measles Rubella Strategic Framework. N. CROWCROFT. WHO. 15 min. Discussion. 40 min.	FOR DECISION SAGE is requested to appraise the Measles and Rubella Strategic Framework	1h
12:15	IA2030: Development of the IA2030 Monitoring, Evaluation, and Action and Ownership and Accountability Frameworks - Session 8 Overview of IA2030 ME&A Framework Development. E. MAST. US CDC. 20 min. Emerging IA2030 Ownership & Accountability mechanism options. A. LINDSTRAND. WHO. 10 min. Discussion. 30 min.	FOR DISCUSSION The session will centre on two key objectives: 1. Share updates from the Immunization Agenda 2030 (IA2030) Monitoring & Evaluation Task Force and IA2030 Core Team of partners, including: <ul style="list-style-type: none"> Proposed IA2030 Strategic Priority (SP) Objective indicators Proposed Impact Goal (IG) indicators Proposed options to set targets for IG and SP Objective indicators Emerging design options for the Ownership & Accountability (O&A) mechanism 2. Receive guidance from SAGE on: <ul style="list-style-type: none"> ME&A Framework architecture and target setting options Emerging O&A mechanism options 	1h
13:15	Break	Break	30 min.
13:45	Pneumococcal Vaccines: Considerations for use in older adults and use in outbreak settings – Session 9 <u>Advice to countries on use of pneumococcal vaccines in national programmes to vaccinate older adults.</u> Introduction to session, background, and key questions. A. POLLARD. SAGE Member. 5 min. Summary overview of evidence. A. POLLARD. SAGE Member. 20 min. Proposals from the SAGE Working Group. A. POLLARD. SAGE Member. 5 min. Discussion. 30 min. <u>Pneumococcal outbreaks and strategies for prevention and response</u> Summary of Evidence. M. KNOLL. Johns Hopkins University. 10 min. Conclusions and Proposals. A. POLLARD. SAGE Member. 5 min. Discussion. 15 min.	FOR DECISION Present SAGE with a review of pneumococcal disease in older adults (i.e., over 50 years); pneumococcal vaccine efficacy, effectiveness, and safety in older adults; herd effects due to childhood pneumococcal vaccination programmes; and implementation experience of adult pneumococcal vaccination programmes, including coverage, feasibility, and cost. SAGE is requested to address the following question: From a public health perspective, what key aspects should be considered by a country when determining whether to include adult pneumococcal vaccination in its national immunization programme? SAGE is asked to answer the following question: Is there evidence to support use of pneumococcal conjugate vaccines to prevent or mitigate outbreaks of pneumococcus?	1h 30 min.
15:15	Vaccine Innovation Prioritization Strategy (VIPS) - Session 10	FOR DISCUSSION Share with SAGE the process and outcomes of VIPS with a decision to prioritise 3 innovations / approaches: i) microarray patches, ii) heat stable	45 min.

5 October 2020

<p>The Vaccine Innovation Prioritization Strategy: Process, outcomes and next steps. M. MENOZZI-ARNAUD. GAVI. and B. GIERING. WHO. 20 min.</p> <p>Perspective from the VIPS Alliance Steering Committee chair. J ABRAMSON. Wake Forest University. 5 min.</p> <p>Discussion. 20 min.</p>	<p>and Controlled Temperature Chain qualified vaccines, iii) barcodes on primary packaging, for which the VIPS Alliance will further collaborate to advance development, policy and access.</p> <p>Seek endorsement from SAGE on:</p> <ul style="list-style-type: none">- Innovative vaccine delivery technologies are needed to address immunisation barriers and achieve immunisation coverage and equity goals, including reaching zero-dose children and missed communities.- VIPS must now engage with regional immunisation, regulatory and policy-making fora to ensure validation of the perceived benefits and feasibility of the priority innovations and support to accelerate availability and access.-The VIPS Alliance has identified the key, high level workstreams that will advance vaccine product innovation in a measurable way.
16:00 End of the Plenary Meeting	

Thursday, 08 October 2020

12:00 Closed SAGE meeting	Recap of day 3. Other important discussion items.	2h
14:00 End of the meeting		